Protocols
BICYCLE-BT5528-100 Phase I/II OPEN TO ACCRUAL
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression
CHUGAI-SPK101JG Phase I OPEN TO ACCRUAL
A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors
DRAGONFLY-DF6002-001 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
GLYCONEX-GNX-001 Phase I OPEN TO ACCRUAL
A Phase I Study of GNX102 in Patients with Advanced Solid Tumors
HOFFMANN-BO41932-TAPISTRY Phase II OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
IIT-GEORGE-I-PREDICT Phase I/II OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
NRG-GY022 Phase N/A OPEN TO ACCRUAL
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
VMONCOLOGY-VMO-01C Phase I OPEN TO ACCRUAL
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma